NCT05662215

A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3828136 in Healthy Participants

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 57 (actual)
• Sponsor: Cytokinetics · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

1. Learn about the safety and tolerability of CK-3828136 after a single dose and multiple doses in healthy subjects. 2. Find out how much CK-3828136 is in the blood after a single dose and multiple doses. 3. Determine the effect different doses of CK-3828136 on the pumping function of the heart.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	CK-3828136	CK-3828136
DRUG	Placebo for CK-3828136	Placebo for CK-3828136

Timeline

• Start date: 2022-12-06
• Primary completion: 2023-08-08
• Completion: 2023-08-08
• First posted: 2022-12-22
• Last updated: 2024-10-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study